Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients.

about

Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients.

Item

http://www.wikidata.org/entity/Q43608491

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Circulating microparticles are ...... all cell lung cancer patients.

@en

Circulating microparticles are ...... all cell lung cancer patients.

@nl

type

Item

label

Circulating microparticles are ...... all cell lung cancer patients.

@en

Circulating microparticles are ...... all cell lung cancer patients.

@nl

prefLabel

Circulating microparticles are ...... all cell lung cancer patients.

@en

Circulating microparticles are ...... all cell lung cancer patients.

@nl

P1476

Circulating microparticles are ...... mall cell lung cancer patients

@en

P2093

Chia-Cheng Tseng

http://www.w3.org/2001/XMLSchema#string

Chin-Chou Wang

http://www.w3.org/2001/XMLSchema#string

Hon-Kan Yip

http://www.w3.org/2001/XMLSchema#string

Huang-Chih Chang

http://www.w3.org/2001/XMLSchema#string

Kuo-Tung Huang

http://www.w3.org/2001/XMLSchema#string

Meng-Chih Lin

http://www.w3.org/2001/XMLSchema#string

Yu-Mu Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

One hundred years of lung cancer

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Lung cancer

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing.

Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis.

P304

75952-75967

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.18372

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29100283

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

5652677

http://www.w3.org/2001/XMLSchema#string